Multiple Sclerosis | Access and Reimbursement | EU5 | 2018

Market Outlook

In the EU5, access to disease-modifying therapies (DMTs) for the treatment of multiple sclerosis is impacted by multiple factors including specific indication labeling, monitoring requirements, health technology assessment decisions, patient access agreements, and regional variations in reimbursement. New therapies, including late-phase pipeline products (Novartis’s siponimod, Celgene’s ozanimod, Actelion’s ponesimod, and Novartis’s ofatumumab) and recent entrants whose HTAs are still under way (Roche’s Ocrevus and Merck’s Mavenclad) will be required to demonstrate cost-effectiveness and therapeutic benefit over existing brands to optimize pricing and reimbursement terms. Additionally, competition from emerging generics (glatiramer acetate, fingolimod) will introduce a new dynamic into pricing and reimbursement decisions in what has been a brand-only market.

Questions Answered

• How do EU5 payers reimburse drugs for the treatment of MS? What restrictions do they impose, and how, if at all, do these impact physician prescribing practices?
• How will prescribers incorporate disease-modifying therapies such as Ocrevus and Mavenclad into their treatment algorithm? What market access challenges will these premium-priced agents face in the current European economic climate?
• What key market access challenges do emerging MS agents face? How might the approval of a therapy such as siponimod alter current prescribing practices?

Product Description

Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Markets covered: France, Germany, Italy, Spain, United Kingdom.

Primary research:

• Survey of 250 neurologists across the EU5 (50 per country).
• Interviews with 10 EU5 payers (2 per country).

Key companies: Roche, Merck, Novartis, Receptos, Celgene.

Key drugs: established disease-modifying therapies, and recently-launched/emerging therapies such as Ocrevus, Mavenclad, siponimod, and ozanimod.

Content highlights:

• Actionable recommendations to optimize market access.
• Market access success and stumbles.
• Market access roadblocks.
• Reimbursement dynamics.
• The impact of pricing and reimbursement, policy, and coverage on prescribing.
• Market access outlook for emerging therapies.